GE Healthcare wins oligo fit out in China

By Flora Southey contact

- Last updated on GMT


Related tags: Dna

RiBoBio has chosen GE Healthcare to equip its oligonucleotide API facility in Guangzhou, China.

Under the agreement, GE Healthcare Life Sciences will install its laser-based, cell imagine technology – IN Cell Analyzer 6500HS – and its ÄKTA OligoProcess platform, used to synthesise kilogram quantities of oligonucleotides.

Oligonucleotides – chemically synthesised short nucleic acid polymers designed to fuse with DNA or ribonucleic acid (RNA) sequences – are designed to treat infectious, and genetic diseases, as well as some cancers.

According to RiBoBio, the firms aim to “jointly build Asia’s largest oligonucleotide drug development and manufacturing facility in China.”

A RiBoBio spokesperson told us the site will not uniquely target Chinese firms.

“RiBoBio will make oligonucleotide APIs ​[active pharmaceutical ingredients] to provide CDMO ​[contract development and manufacturing organisation] services for clients worldwide,” ​said the spokesperson.

The firm did not disclose the cost of the facility, but said it expects the site to be operational by the end of 2018.

US oligo boost

The US has shown an increased interest in oligo treatments, with recent facility expansions in central and north-east states.

In August, 2016, Agilent announced​ plans for a nucleic acid API manufacturing plant in Colorado, and in July this year, Nitto Denko Avecia said​ it would launch its expanded oligo API facility in Massachusetts.

GE Healthcare and CordenPharma also announced​ a strategic agreement for oligonucleotide development in July, under which GE Healthcare’s Dharmacon will offer early-phase, and CordenPharma later phase, services.  

Related topics: Contract Manufacturing

Related news

Related products

show more


Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.


Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers

Follow us


View more